We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

30 hedge funds and large institutions have $5.26M invested in Corbus Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,400% more call options, than puts

Call options by funds: $260K | Put options by funds: $4K

298% more capital invested

Capital invested by funds: $1.32M → $5.26M (+$3.94M)

17.04% more ownership

Funds ownership: 0.32% → 17.36% (+17%)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

52% less funds holding

Funds holding: 63 → 30 (-33)

89% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 36

Holders
30
Holders Change
-33
Holders Change %
-52.38%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
13
Closed
36
Calls
$260K
Puts
$4K
Net Calls
+$256K
Net Calls Change
+$234K

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$783K
2
SCM
Sio Capital Management
New York
+$656K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$195K
4
BFM
Boothbay Fund Management
New York
+$160K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$59.9K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$63K
2
Wells Fargo
Wells Fargo
California
-$49.5K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$33.9K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$31K
5
BlackRock
BlackRock
New York
-$27.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
51
Pinnacle Associates
New York
– -$2.05K -619 Closed
ECM
52
ExodusPoint Capital Management
New York
– -$2K -562 Closed
KAS
53
Kestra Advisory Services
Texas
– -$1.86K -560 Closed
AWM
54
Aries Wealth Management
Maine
– -$1.7K -513 Closed
HighTower Advisors
55
HighTower Advisors
Illinois
– -$2K -503 Closed
HSA
56
HBK Sorce Advisory
Pennsylvania
– -$2K -458 Closed
GL
57
Graypoint LLC
New York
– -$1.48K -447 Closed
SG
58
StoneX Group
New York
– -$1.45K -437 Closed
ML
59
McAdam LLC
Pennsylvania
– -$6K -334 Closed
AWAG
60
ARS Wealth Advisors Group
Florida
– -$1.1K -333 Closed
Citadel Advisors
61
Citadel Advisors
Florida
– -$762 -230 Closed
AWM
62
Activest Wealth Management
Florida
– -$125 -37 Closed
CS
63
Comerica Securities
Michigan
– -$66 -20 Closed
PA
64
Parallel Advisors
California
– -$22 -7 Closed
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
– -$11 -3 Closed
1 2
3

CRBP Hedge Fund Activity: Q1 2023 in Review

30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2023, worth a combined $5.26M — up 298% from $1.32M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CRBP and 4 opened new positions — a net loss of 32 holders — while 13 trimmed existing stakes and 7 added.

The largest buyer was Ikarian Capital, adding an estimated $783K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $63K sold.

  • 30 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2023, down from 63 in Q4 2022.
  • Funds reported $5.26M of Corbus Pharmaceuticals stock for Q1 2023, up 298% quarter-over-quarter.
  • 4 funds opened new Corbus Pharmaceuticals positions in Q1 2023 and 36 closed out, a net change of -32 holders.
  • The largest Corbus Pharmaceuticals buyer in Q1 2023 was Ikarian Capital, an estimated $783K added.
  • The largest Corbus Pharmaceuticals seller in Q1 2023 was Two Sigma Investments, an estimated $63K sold.

Based on aggregated 13F filings for Q1 2023.